momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (12041)	1/16/2019 1:58:56 PM
From: scaram(o)uche	of 12215

>> AXGN << Never owned it, never looked closely. Today, CCO gets a separation agreement. Guy got fired, but looks like he had some leverage. Then they issue an absurd release, "Study Supports Company’s Planned Biologic License Application (BLA).....", when the actual punchline is "AxoGen has submitted the interim analysis to the FDA for review with the intention of obtaining agreement on next steps, which could include continuing study enrollment." Continued enrollment would be a disaster, given that every additional patient enrolled will restart the one year timer. What gives? And how could a release re. full enrollment lead to "*study supports*"? Is there any way on this wonderful globe that the release is not meant to be misleading?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next